Assessing the dose-dependency of allometric scaling performance using physiologically based pharmacokinetic modeling

被引:36
作者
Kirman, CR
Sweeney, LM
Meek, ME
Gargas, ML
机构
[1] Sapphire Grp Inc, Beachwood, OH 45431 USA
[2] Sapphire Grp Inc, Dayton, OH 45431 USA
[3] Hlth Canada, Ottawa, ON K1A 0L2, Canada
关键词
allometric scaling; PBPK modeling; dose-dependency; risk assessment; interspecies extrapolation;
D O I
10.1016/j.yrtph.2003.07.004
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
The performance of allometric scaling of dose as a power of body weight under a variety of extrapolation conditions with respect to species, route, exposure intensity, and mechanism/mode of action, remains untested in many cases. In this paper, animal-human internal dose ratio comparisons have been developed for 12 chemicals (benzene, carbon tetrachloride, chloroform, diisopropylfluorophosphate, ethanol, ethylene oxide, methylene chloride, methylmercury, styrene, tetrachloroethene, trichloroethene, and vinyl chloride). This group of predominantly volatile and lipophilic chemicals was selected on the basis that their kinetics have been well-studied and can be predicted in mice, rats, and humans using physiologically based pharmacokinetic (PBPK) models. PBPK model predictions were compared to the allometric scaling predictions for interspecies extrapolation. Recommendations for the application of the allometric scaling are made with reference to internal dose measure (mode of action) and concentration level. The results of this assessment generally support the use of scaling factors recommended in the published literature, which includes scaling factors of 1.0 for risk assessments in which toxicity is attributed to the parent chemical or stable metabolite, and -0.75 for dose-response assessments in which toxicity is attributed to the formation of a reactive metabolite from an inhaled compound. A scaling factor of 0.75 is recommended for dose-response assessments of orally administered compounds in which toxicity is attributed to the parent chemical or stable metabolite and 1.0 for risk assessments in which toxicity is attributed to the formation of a reactive metabolite from a compound administered by the oral route. A dose-dependency in the results suggests that the scaling factors appropriate at high exposures may differ from those at low exposures, primarily due to the impact of saturable metabolism. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:345 / 367
页数:23
相关论文
共 39 条
[1]   PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING WITH DICHLOROMETHANE, ITS METABOLITE, CARBON-MONOXIDE, AND BLOOD CARBOXYHEMOGLOBIN IN RATS AND HUMANS [J].
ANDERSEN, ME ;
CLEWELL, HJ ;
GARGAS, ML ;
MACNAUGHTON, MG ;
REITZ, RH ;
NOLAN, RJ ;
MCKENNA, MJ .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1991, 108 (01) :14-27
[2]   PHYSIOLOGICALLY BASED PHARMACOKINETICS AND THE RISK ASSESSMENT PROCESS FOR METHYLENE-CHLORIDE [J].
ANDERSEN, ME ;
CLEWELL, HJ ;
GARGAS, ML ;
SMITH, FA ;
REITZ, RH .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1987, 87 (02) :185-205
[3]   Uncertainty/safety factors in health risk assessment: Opportunities for improvement [J].
Beck, BD ;
Clewell, HJ .
HUMAN AND ECOLOGICAL RISK ASSESSMENT, 2001, 7 (01) :203-207
[4]   COMPUTER-SIMULATION OF THE LACTATIONAL TRANSFER OF TETRACHLOROETHYLENE IN RATS USING A PHYSIOLOGICALLY-BASED MODEL [J].
BYCZKOWSKI, JZ ;
KINKEAD, ER ;
LEAHY, HF ;
RANDALL, GM ;
FISHER, JW .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1994, 125 (02) :228-236
[5]  
CASNADY GA, 2000, TOXICOL APPL PHARM, V165, P1
[6]   Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment [J].
Clewell, HJ ;
Gentry, PR ;
Covington, TR ;
Gearhart, JM .
ENVIRONMENTAL HEALTH PERSPECTIVES, 2000, 108 :283-305
[7]   A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment [J].
Clewell, HJ ;
Andersen, ME ;
Barton, HA .
ENVIRONMENTAL HEALTH PERSPECTIVES, 2002, 110 (01) :85-93
[8]   DEVELOPMENT OF A PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL FOR CHLOROFORM [J].
CORLEY, RA ;
MENDRALA, AL ;
SMITH, FA ;
STAATS, DA ;
GARGAS, ML ;
CONOLLY, RB ;
ANDERSEN, ME ;
REITZ, RH .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1990, 103 (03) :512-527
[9]   A PHYSIOLOGICAL PHARMACOKINETIC MODEL FOR STYRENE AND STYRENE-7,8-OXIDE IN MOUSE, RAT AND MAN [J].
CSANADY, GA ;
MENDRALA, AL ;
NOLAN, RJ ;
FILSER, JG .
ARCHIVES OF TOXICOLOGY, 1994, 68 (03) :143-157
[10]   INTERSPECIES SCALING OF REGIONAL DRUG DELIVERY [J].
DEDRICK, RL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1986, 75 (11) :1047-1052